Servais, Laurent ; Université de Liège - ULiège > Département des sciences cliniques
Moreno, Cristiane Araujo Martins ; Departamento de Neurologia, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, São Paulo, Brazil
Language :
English
Title :
Spinal muscular atrophy in Brazil: from individual treatment to global management.
Aragon-Gawinska, K., Mouraux, C., Dangouloff, T., Servais, L., Spinal muscular atrophy treatment in patients identified by newborn screening-a systematic review. Genes (Basel), 14, 2023, 1377.
Giannetti, J., Januário, J., Milanez, L., Sacramento, A., Moura, A., Braga, T., et al. Can 5q SMA neonatal screening be a sustainable reality in middle-income countries? The experience of Minas Gerais state in Brazil. Neuromuscul Disord, 43(Suppl. 1), 2024, 104459.
Oliveira Netto, A.B., Brusius-Facchin, A.C., Lemos, J.F., Pasetto, F.B., Brasil, C.S., Trapp, F.B., et al. Neonatal screening for spinal muscular atrophy: a pilot study in Brazil. Genet Mol Biol, 46, 2023, e20230126.
Zanoteli, E., Araujo, A.P., Becker, M.M., Fortes, C.P., França, M.C. Jr, Machado-Costa, M.C., et al. Consensus from the Brazilian Academy of Neurology for the diagnosis, genetic counseling, and use of disease-modifying therapies in 5q spinal muscular atrophy. Arq Neuropsiquiatr 82 (2024), 1–18.
de Albuquerque, A.L., Chadanowicz, J.K., Bevilacqua, I.P., Staub, A.L., Winckler, P.B., da Silva, P.Z., et al. Clinicogenetic characterization and response to disease-modifying therapies in spinal muscular atrophy: real-world experience from a reference center in Southern Brazil. J Pediatr (Rio J) S0021-7557:24 (2024), 00126–00128, 10.1016/j.jped.2024.07.011.
Mendonça, R.H., Matsui, C. Jr, Polido, G.J., Silva, A.M., Kulikowski, L., Torchio Dias, A., et al. Intragenic variants in the SMN1 gene determine the clinical phenotype in 5q spinal muscular atrophy. Neurol Genet, 6, 2020, e505.
Kretzschmar, A.K., Teixeira, E., Galato, D., Silva, E.N., Judicialization of Zolgensma in the Ministry of Health: costs and clinical profile of patients. Rev Saude Publica, 58, 2024, 36.
Weiß, C., Becker, L., Friese, J., Blaschek, A., Hahn, A., Illsinger, S., et al. Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH region: a population-based observational study. Lancet Reg Health Eur, 47, 2024, 101092.
Dangouloff, T., Hiligsmann, M., Deconinck, N., D'Amico, A., Seferian, A.M., Boemer, F., et al. Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. Dev Med Child Neurol 65 (2023), 67–77.
Vrščaj, E., Dangouloff, T., Osredkar, D., Servais, L., Newborn screening programs for spinal muscular atrophy worldwide in 2023. J Neuromuscular Dis, 2024, 10.1177/22143602241288095.
Dangouloff, T., Thokala, P., Stevenson, M.D., Deconinck, N., D'Amico, A., Daron, A., et al. Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium. Neuromuscul Disord 34 (2024), 61–67.
Dangouloff T., Botty C., Beaudart C., Servais L., Hiligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 202;16:47.
Laugwitz, L., Mechtler, T.P., Janzen, N., Oliva, P., Kasper, A.R., Teunissen, C.E., et al. Newborn screening and presymptomatic treatment of metachromatic leukodystrophy. N Engl J Med, 2024, 10.1056/NEJMc2407165.
Markati, T., Duis, J., Servais, L., Therapies in preclinical and clinical development for Angelman syndrome. Expert Opin Investig Drugs 30 (2021), 709–720.
